Bleeding Disorders Therapeutics Market Report and Forecast 2025-2034

Global Market Likely to be Driven by Advancements in Treatment Systems

Hemophilia and von Willebrand disease are common congenital bleeding disorders. Treatments have focused on replacement of the missing coagulation factor to avert or treat bleeding. Novel technologies and understanding of hemostasis have led to the development of several promising novel therapies for hemophilia and von Willebrand disease. Emergent bypass agents, such as zymogen-like factor IXa and Xa molecules are being developed; a bispecific antibody, emicizumab, has exhibited efficacy in a phase 3 trial in individuals with hemophilia A and inhibitors.

Novel Compounds Show Promise

New compounds in development target tissue factor pathway inhibitor, protein C/S system, and antithrombin to modify the hemostatic balance, and modern approaches employing modified factor VIII molecules are under tests to prevent and eradicate antibodies in hemophilia A. The first recombinant von Willebrand factor (VWF) product has been approved; it possesses VWF multimer content and does not carry factor VIII. These novel approaches may provide superior routes of administration, better dosing regimens, and enhanced efficacy for inhibition and treatment of bleeding in congenital bleeding disorders. Such developments are expected to stimulate the global bleeding disorders therapeutics market.

In von Willebrand disease (vWD), an individual either does not possess the normal levels of an important protein, or the protein does not function the way it should, therefore, the body is unable to form a stable clot. Around one percent of the population suffers from some form of the illness. The disease is inherited from one or both parents, and affects both men and women.

Hemophilia is a serious and rare X-chromosome linked congenital bleeding disorder affecting the blood's ability to clot; this means that individuals suffering from hemophilia bleed for durations than normal. Hemophilia is of two types – hemophilia A and hemophilia B. Nearly eighty percent of all people suffering from hemophilia are diagnosed with hemophilia A. The condition is also known as factor VIII (8) deficiency, because it is a lack of the clotting factor – factor VIII – that causes the condition. Almost twenty percent of people with hemophilia are diagnosed with hemophilia B or factor IX deficiency (caused by a lack of clotting factor IX).

Hemophilia and rare bleeding disorders are linked to different types of coagulation factors; therefore, different treatments are available. Prevalent therapies are dispensed by infusion therapy injected into a vein or administered subcutaneously. Replacement therapy may be administered to treat a bleeding episode in progress. It can also be carried out at home on regular intervals to help avert bleeding episodes. Receiving continuous replacement therapy is necessary for some individuals suffering from hemophilia.

Fifteen other bleeding disorders have been identified along with hemophilia A and B. These include factor VII deficiency, factor XIII deficiency, factor I (fibrinogen) deficiency, afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, factor II deficiency, factor V deficiency, factor X deficiency, factor XI deficiency (hemophilia C), Glanzmann’s thrombasthenia, Bernard-Soulier syndrome, platelet storage pool deficiency, and acquired hemophilia.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Advancing Treatments in Hemophilia and Rare Blood Disorders Likely to Boost the Market

Leading companies are combining experience in protein design with collaborations in the international scientific community to develop effective and safe treatments for individuals with hemophilia and other rare bleeding disorders. Scientists are testing innovative, long-acting and subcutaneous treatment solutions for rare blood disorders and hemophilia. Such solutions seek to reduce current treatment burden and improve clinical outcomes. These solutions would be complemented by studies on oral treatments and gene therapy. Innovative treatments being tested for bleeding disorders include gene therapy, anti-tissue factor pathway inhibitor (TFPI) or anti-TFPI, encapsulated cell therapy, and RNA interference (RNAi) therapy targeting antithrombin.

Global Bleeding Disorders Therapeutics Market Segmentation

Key Industry Players in the Global Bleeding Disorders Therapeutics Market

The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• CSL Behring
• Bayer AG
• Novo Nordisk A/S
• Biogen Inc.
• Sanofi SA
• Octapharma AG
• Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.